Fichier PDF

Partage, hébergement, conversion et archivage facile de documents au format PDF

Partager un fichier Mes fichiers Convertir un fichier Boite à outils Recherche Aide Contact

1 s2.0 S1533002811001071 main .pdf

Nom original: 1-s2.0-S1533002811001071-main.pdf

Ce document au format PDF 1.7 a été généré par Elsevier / ; modified using iText 5.0.3 (c) 1T3XT BVBA, et a été envoyé sur le 28/06/2012 à 00:15, depuis l'adresse IP 41.107.x.x. La présente page de téléchargement du fichier a été vue 1475 fois.
Taille du document: 271 Ko (5 pages).
Confidentialité: fichier public

Télécharger le fichier (PDF)

Aperçu du document


Preoperative Radiation Therapy for Upper Rectal
CancerT3,T4/Nx: Selectivity Essential
Sarah Popek,1 Vassiliki Liana Tsikitis,1 Lisa Hazard,2 Alfred M. Cohen1
This review explores the current available literature regarding the role of neoadjuvant therapy for upper locally
advanced rectal cancers (ⱖ10cm-15cm). Although there is a paucity of data evaluating the outcomes of preoperative
chemoradiation for upper rectal cancers the authors suggest that T3N0 tumors will not likely benefit from radiation
and that treatment of T4N0 should be individualized.
Clinical Colorectal Cancer, Vol. xx, No. x, xxx © 2011 Published by Elsevier Inc.
Keywords: Neoadjuvant therapy, Rectal cancer, T3, T4Nx

The past two decades have seen major advances in surgical treatment and combined modality therapy of patients who have rectal
cancer. For patients who have mid and lower rectal cancer (ⱕ 10 to
12 cm) the standard of surgical care now includes total mesorectal
excision (TME), which has been shown to significantly decrease local
recurrence rates.1 Locoregional recurrence is further reduced with
the combination of optimal surgery and chemoradiation therapy.
Clinical trials now support the use of preoperative (neoadjuvant)
sequencing as the preferred strategy for transmural and/or clinical
node positive tumors. It remains controversial as to the selective
application of this paradigm when the cancer is above the peritoneal
reflection.2 In the 7th edition of the American Joint Committee on
Cancer (AJCC) Cancer Staging Manual, upper rectal tumors are
defined as partially peritonalized, versus tumors of the mid and lower
rectum, which are not peritonalized (Figure 1). The significance of
this difference translates into a different T stage for transmural upper
and lower rectal tumors. For example, for a mid-low rectum, a transmural tumor is always a T3 lesion, whereas a transmural upper rectal
tumor is classified as a T4 lesion when located anteriorly, but as a T3
lesion when located posteriorly (Figure 1). Anterior T4 lesions, node
negative, frequently receive adjuvant postoperative chemotherapy
only. Patients with T3N0 lesions have a better prognosis compared
to patients with other types of locally advanced rectal cancer, as

Department of Surgery, Section of Surgical Oncology
Department of Radiation Oncology, University Medical Center, University of
Arizona, Tucson AZ 85734


Submitted: Apr 8, 2011; Accepted: Jun 14, 2011
Address for correspondence: Alfred Cohen, MD, FACS, FASCRS, 1501 N Campbell
Ave, Tucson, Arizona 85724-5131
Tel: (520) 626-6788; Fax: (520) 626-7785; e-mail contact: acohen@surgery.

1533-0028/$ - see frontmatter © 2011 Published by Elsevier Inc.
doi: 10.1016/j.clcc.2011.06.009

reflected by the modifications made in the 7th edition of the AJCC
cancer staging manual.
It has been well-demonstrated that neoadjuvant radiotherapy
(RT) improves local recurrence rates in locally advanced rectal cancer
for which the circumferential radial margin (CRM) is the most important prognostic marker of recurrence.2-4 For upper rectal tumors
located above the peritoneal reflection (ⱖ 10 to 12 cm), one could
argue that circumferential margin is free from the anatomically restrictive pelvis and clear radial margins more feasible to obtain. In
addition, it remains unclear if neoadjuvant RT has the same efficacy
and results with upper rectal lesions. Although, when cancer-specific
survival was examined, upper rectal cancers behaved more like mid
and lower rectal than sigmoid cancers. Local recurrence was not
This review article examines the current available literature concerning the treatment paradigms and treatment outcomes for T3T4
Nx upper rectal cancers.
In the last decade, neoadjuvant RT has emerged as the preeminent mode of treatment for locally advanced rectal cancer in
terms of local recurrence rates and toxicity. In 2004, the German
Rectal Cancer Study Group compared local recurrence and overall survival rates for rectal cancer patients treated with neoadjuvant versus adjuvant chemoradiation therapy (CMT) and found
significantly improved rates of local recurrence in the neoadjuvant
arm (6% versus 13%, P ⫽ .006), yet no difference in overall
survival.6 A few years later, the MRC CR07/NCIC CTG C0167
study confirmed the superiority of neoadjuvant RT compared to
selective adjuvant RT, the latter of which delivered radiation only
in patients with close circumferential margin. This study demonstrated a 61% relative risk reduction in local recurrence in the
neoadjuvant arm (P ⬍ .0001). A second critical benefit of neoadjuvant RT is the decrease in rates of acute and chronic toxicity,

Clinical Colorectal Cancer Month 2011


Preoperative RT for Upper Rectal Cancer
Figure 1 Upper Rectal Tumors are Defined as Partially
Peritonalized, Versus Tumors of the Mid and Lower
Rectum, Which are not Peritonalized








translating into more patients completing treatment with less
postoperative anorectal dysfunction.8-11

Imaging for Staging of Rectal
The assumption behind asking the question, “Do upper rectal
cancer patients benefit from neoadjuvant radiotherapy?” is that these
patients can be accurately identified preoperatively. In fact, one of
the main obstacles in answering this question is the ambiguity of
preoperative clinical staging. Currently in the United States, preoperative staging consists of a combination of imaging modalities including computed tomography (CT), endorectal ultrasound
(ERUS), and magnetic resonance imaging (MRI). The decision of
which modality to pursue is often based on local expertise and availability. In contrast, in Europe, preoperative staging uses high-resolution MRI to estimate the CRM. Whereas in the United States,
currently all T3N0 patients are offered neoadjuvant CMT and adjuvant chemotherapy. In Europe, the estimated CRM determines
which patients will receive neoadjuvant RT.12
The Magnetic Resonance Imaging and Rectal Cancer European
Equivalence Study (MERCURY) trial, published in 2006, set the
standard for preoperative assessment of CRM with a specificity of
92% using high-resolution MRI.13 In this trial, the authors used
high-resolution MRI to estimate the CRM in 408 consecutive rectal
cancer patients. These estimates were then contrasted to the actual
pathologic findings. Although distance from the anal verge is one of
the variables studied, the authors do not discuss variation in accuracy
based on tumor location. One important limitation discussed is the
inaccuracy of lymph node identification. MRI is able to identify
lymph nodes greater than 1 cm in size. However, although sugges-


Clinical Colorectal Cancer Month 2011

tive, size is not pathognomic of malignancy. Several smaller studies
have evaluated and compared the efficacy of CT scanning to MRI
with mixed results. Studies have shown that multidetector-row CT14
has a poor accuracy rate in evaluating CRM in low rectal cancers and
moderate accuracy in mid to high rectal cancers, but is not superior
to MRI.14,15
ERUS was first used to stage rectal cancer in 1985,15 and use of
this modality has increased. ERUS has established itself as a key
component of preoperative staging for rectal cancer,16 however, exactly where in the paradigm of preoperative imaging it lies has yet to
be refined. A small study published in 200817 comparing ERUS and
MRI in preoperative staging for rectal cancer found that accuracy of
T staging was slightly higher with MRI than ERUS (85% versus
89%), whereas both modalities had poor identification of lymph
node involvement (76% versus 74%). A recent meta-analysis evaluating the sensitivity of ERUS for identification of lymph node involvement in 2732 patients demonstrated a pooled sensitivity of
73.2% (95% confidence interval [95% CI] 70.6-75.6) and specificity of 75.8% (95% CI 73.5-78).18 Enthusiasm for ERUS has waned
recently, reflecting the recent trend toward lower rates of accuracy
published in the literature, which has prompted concerns about publication bias19,20 or increased use by inexperienced physicians.19
There has been suggestion that the addition of fine-needle aspiration
to ERUS would add a significant diagnostic benefit, however, the
data so far has not borne this out.21
A meta-analysis from the Netherlands22 compared the sensitivity
and specificity of all three imaging techniques (ERUS, CT, and
MRI) in preoperative staging for rectal cancer. ERUS and MRI had
comparable sensitivity in estimating invasion of the muscularis propria (94%, 95% CI 90-97 versus 94%, 95% CI 89-97), but ERUS
was significantly more specific than MRI (86%, 95% CI 80-90 versus 69%, 95% CI 52-82, P ⫽ .02). No data was available for CT. In
assessing perirectal tissue invasion, ERUS was significantly more sensitive than either CT or MRI (90%, 95% CI 88-92 versus 79%, 95%
CI 74-84, versus 82%, 95% CI 74-87, P ⫽ .003), although the
specificities were similar (75%, 95% CI 69-81 versus 78%, 95% CI
73-83 versus 76%, 95% CI 65-84). Lastly, there was no significant
difference found between the three modalities in diagnosing adjacent
organ or lymph node involvement. The authors conclude that ERUS
is the most accurate modality for preoperative staging of locally advanced rectal cancer, however, they note the continued inaccuracy of
identification of lymph node involvement is a significant limitation
of all three imaging modalities. Upper rectal tumors are even more
difficult to study and accurately differentiate between a T3 and T4
Nx lesion with a rigid ERUS. Currently ERUS and MRI are the
standard modalities used in the United States for staging of rectal

Local Recurrence
There are three major trials evaluating local recurrence in rectal
cancer with neoadjuvant and adjuvant therapy that include data
based on tumor location (Table 1). The first trial, the Swedish Rectal
Cancer Trial23 published in 1997, was a landmark article demonstrating significant improvements in local control and overall survival
for patients undergoing neoadjuvant short-course RT. The study
population was composed of stage I to III patients diagnosed using

Sarah Popek et al
Table 1 Local Recurrence in Rectal Cancer With Neoadjuvant and Adjuvant Therapy
Trial (Year Results

No. of Patients Tumor Distance
in Upper
From Anal
Rectal Subset
Verge (cm)


Outcome (%): Local


Neoadjuvant short-course
RT vs surgery alone

11% vs 27%
(P ⬍ .001)



Neoadjuvant short-course
RT (standard TME ) vs
surgery alone

2.4% vs 8.2%
(P ⬍ .001)



Neoadjuvant long-course
RT ⫹ chemotherapy vs.
adjuvant long-course
RT ⫹ chemotherapy

6% vs 13%
(P ⫽ .006)


No. of

Swedish Rectal Cancer
Trial (1997)




Dutch TME Trial (2001)



German Rectal Cancer
Study Group (2004)





MSKCC (2008)

Abbreviations: MSKCC ⫽ Memorial Sloan-Kettering Cancer Center; RCT ⫽ randomized controlled trial; RT ⫽ radiation therapy; TME ⫽ total mesorectal excision.

barium enema and rigid proctoscope, 27% of whom had upper rectal
lesions (⬎ 11 cm from anal verge). The authors found that neoadjuvant treatment with short-course RT had a significant effect on
decreasing rates of local recurrence for mid and low rectal tumors
(P ⬍ .001, P ⫽ .003), however, the effect on upper rectal tumors was
not significant (P ⫽ .3) on long-term follow-up.24
The Dutch TME trial,25 the first trial to standardize surgical therapy, also found a significant correlation between local recurrence
rates and tumor location within the rectum. Of the 1805 patients
included in the trial, 30% had upper rectal tumors (10.1 to 15 cm
from anal verge), 40% were mid-rectal (5.1 to 10 cm), and 30% were
lower rectal (⬍ 5 cm) tumors as determined by flexible endoscopy.
The patient population was also included all stages of disease, the
majority of whom were stage I-III. The data at 2-year follow-up
shows that both mid-rectal tumors and lower rectal tumors had a
significantly higher risk of developing local recurrence compared to
upper rectal tumors (hazard ratio [HR] 2.13, 95% CI 1.13-4.01, P ⫽
.02; HR 2.78, 95% CI 1.22-6.31, P ⫽ .02). However, on univariate
subgroup analysis, patients with upper rectal tumors who were administered neoadjuvant RT were found to have no improvement in
local recurrence rates (P ⫽ .17) compared to the surgery-alone cohort
at 2-year follow-up; these results were confirmed at 5-year follow-up
(P ⫽ .122).26
The third trial, the German CAO/ARO/AIO trial,6 is limited to
patients with T3/4 tumors who were staged with ERUS and CT
scans, 15% of whom had upper rectal lesions (⬎ 10 cm from anal
verge). The authors do not include the data from their subset analysis, only the conclusion that there was no difference in local recurrence outcomes between upper and lower rectal tumors.27
None of the aforementioned trials were designed or powered to
evaluate the benefit of radiation in the subset of patients with T3/
4N0 disease. Nonetheless, the Swedish and Dutch studies suggest
that the absolute benefit of RT in this subset is, if present, a small one.
Gunderson et al28 combined data from five randomized studies to
examine the relationship between survival and relapse and T and N
stage, as well as treatment modalities. They evaluated data from a
total of 3791 patients and used these data to create a risk classification
comprised of four categories (low, intermediate, moderately high,
high) based on local recurrence and survival rates. Higher T stage

lesions are categorized as intermediate-risk based on the overall
5-year survival rate of 75% and local recurrence rate of 9%. The
authors note that patients in subgroups who received neoadjuvant
RT had lower recurrence rates (5% to 10%) compared to patients
who were treated with surgery alone (11%). Unfortunately, they did
not have data concerning tumor location within the rectum; therefore, although the authors extrapolate that trimodality treatment of
intermediate-risk tumors may be excessive and unnecessary, no definitive recommendations can be made at this juncture. Several smaller
studies concerning patients with only T3N0 rectal cancer treated with
surgery alone have reported 5-year local recurrence, systemic recurrence,
and survival rates comparable to cohorts of patients treated with neoadjuvant or adjuvant CMT.29-31 However, these studies do not differentiate tumor location within the rectum and have small patient populations, therefore suggesting the further need into investigating if and
when it is safe to treat T3N0 patients with surgery alone.

Predictors of Local Recurrence
It has been well-established that CRM has important prognostic
value concerning local and distal recurrence in rectal cancer. What
has not been well-established is the relevance of CRM in upper rectal
cancer. In contrast to low and middle tumors constrained by a narrow pelvis, upper rectal tumors are not bound by similar physical
limitations. Thus, it has been hypothesized that CRM has less importance as a prognostic indicator in upper rectal tumors. One study2
comparing the 5-year local and systemic recurrence rates between
patients with positive CRM (n ⫽ 460) and patients with negative
CRM (n ⫽ 44) found that 5-year local recurrence was 35% in patients with a positive CRM compared to 11% in the negative-CRM
group (P ⫽ .010); 5-year systemic recurrence was 60% in the positive-CRM and 25% in the negative-CRM group (P ⬍ .001). Upper
rectal tumors comprised 24% of the negative-CRM group and 23%
of the positive-CRM group; however, there was no significant correlation between tumor location and rate of CRM positivity or negativity (P ⫽ .466). Bernstein et al4 also studied the predictive impact
of CRM after surgery to identify the ideal CRM. The authors looked
at a much larger study group (n ⫽ 3196) than the aforementioned
study and found that patients with CRM of 0 to 2 mm had a local
recurrence of 23.7% compared to 8.9% in patients with wider mar-

Clinical Colorectal Cancer Month 2011


Preoperative RT for Upper Rectal Cancer
gins. Overall survival was 44.5% in the CRM 0-2-mm group and
66.7% in patients with wider margins. In the setting of TME surgery
without RT, the authors found that patients with mid-rectal tumors
are 38% more likely to have local recurrence than upper rectal tumors, and low rectal tumors are 72% more likely to have a local
recurrence (HR 1.38, CI 1.01, 1.89; HR 1.72, CI 1.06, 2.79; P ⫽
.047). They also found a significant correlation between local recurrence and CRM status in upper rectal lesions. They report that a
CRM of 0 to 2 mm nearly doubles the risk of having a local recurrence compared to CRM ⬎ 3 mm (HR 1.97, 95% CI 1.03, 3.77,
P ⫽ .044), suggesting that CRM is relevant in upper rectal tumors.
To conclude, CRM margins and, in particular, CRM margins more
than 2 mm, are critical for all heights of rectal tumors. The MRC
CR077 trial attempted to determine if RT could be delivered selectively to only those patients with close CRM by randomizing patients to
neoadjuvant RT versus adjuvant RT only if CRM was ⬍ 1 mm. Approximately 12% of patients in the selective adjuvant radiation arm had close
margins and received RT. Local recurrence rates were decreased with
neoadjuvant RT compared to selective adjuvant RT. Although this
study suggests that local recurrences are lowest with preoperative radiation, it raises the question of whether clinical predictors of CRM margins, such as an MRI scan, could allow physicians to be able to more
intelligently select patients requiring preoperative therapy.
Another approach to the question of which higher T stage patients
benefit from neoadjuvant RT is to evaluate predictors of recurrence.
In a series of 100 consecutive pT2/T3 N0 patients32 studied over a
period of 6.5 years, lymphovascular invasion, preoperative carcinoembryonic antigen levels ⬎ 5 ng/mL, and patients older than 70
years were factors predictive of poor outcome. The authors of this
study did not include data concerning tumor location within the
rectum, however, they report local and distal recurrence rates of
4.1% and 28.6, respectively, for locally advanced tumors treated with
surgery alone. The authors state that treatment for uT3N0 rectal
cancer is radical surgery with TME and postulate that preoperative
identification of high-risk patients allows refinement of the population of T3N0 patients who receive neoadjuvant RT to those who
truly benefit from it. A study33 published in 2008 designed to address
the questions surrounding optimal management of T3N0 tumors
regardless of tumor height further obfuscates the issue. One hundred
eighty-eight uT3N0 patients were treated with neoadjuvant CMT
followed by surgery. The preoperative stage was compared to the
postoperative pathologic stage. Positive lymph nodes were identified
in 22% of patients. The incidence of involved lymph nodes corresponded to pathologic T stage (ypT0 3%, ypT1 7%, ypT2 20%,
ypT3-4 36%, P ⫽ .001); suggesting that significant preoperative
understaging of rectal cancer occurs in at least 22% of patients. Distance from the anal verge was included as a tumor variable and the
incidence of lymph node positivity was not related to distance from
the anal verge (P ⫽ .58). The authors conclude that the risk of
overtreatment is lower than the risk of undertreatment and recommend that locally aggressive tumors (T3 N0), independent of height
from the anal verge, should be treated with neoadjuvant CMT. Conversely, we could argue that if the pathologic examination has shown
that the upper rectal tumor with adequate CRM was significantly
understaged, or that surgery alone was not optimal, those patients
could receive adjuvant therapy. The potential drawback to this ap-


Clinical Colorectal Cancer Month 2011

proach is a small decrease in local control with adjuvant versus neoadjuvant RT and increase in toxicity as demonstrated in the German
Rectal Cancer Study Group.

There is a paucity of data evaluating the outcomes of locally advanced upper rectal cancer treated with and without neoadjuvant
RT. Although several surrogate markers have been proposed for use
in determining which patients would benefit from neoadjuvant RT,
adequate CRM is the only variable shown in large population studies
to correlate with local recurrence rates in upper rectal cancer.4 Synthesizing the available data suggests that a subset of upper locally
advanced rectal cancers will not experience local recurrence, and in
this subset of patients, neoadjuvant RT only increases toxicity rates,
both acute and chronic.34 Accurate preoperative staging is key to
making informed decisions regarding patient treatment because adjuvant CMT is less effective and more toxic than neoadjuvant CMT.
Careful physical examination combined with rigid proctoscopy can
facilitate defining the clinical location. Looking at the CT scan from
the perspective of tumor location provides additional relevant information, such as, is the patient male or female? And, if the latter, did
she have a prior hysterectomy? Because of the risk of local recurrence
and the associated diminution of quality of life, the importance of
appropriately and selectively treating locally advanced rectal cancer
with neoadjuvant therapy intensifies. We propose that most patients
with T3N0 upper rectal tumors will not benefit from RT, and future
randomized trials should be considered in this subgroup of patients.
Treatment of T4N0 should be individualized. RT is likely of limited
benefit for patients with T4 disease by virtue of anterior extension
through the peritoneal surface, and these patients may be considered
for adjuvant single- modality chemotherapy. Extensive nodal metastases or adherence of a transmural tumor to the pelvic sidewall may
be an indication for postoperative chemoradiation. Local recurrence
genetic signatures, independent of tumor distance from the anal
verge, may represent the next major breakthrough in the management paradigm of locally advanced rectal cancer.

1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the
clue to pelvic recurrence? Br J Surg 1982; 69:613-6.
2. Baik SH, Kim NK, Lee YC, et al. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in
patients with rectal cancer. Ann Surg Oncol 2007; 14:462-9.
3. Nagtegaal ID, van de Velde CJ, Marijnen CA, et al. Low rectal cancer: a call for
a change of approach in abdominoperineal resection. J Clin Oncol 20 2005;
4. Bernstein TE, Endreseth BH, Romundstad P, et al. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009; 96:1348-57.
5. Rosenberg R, Maak M, Schuster T, et al. Does a rectal cancer of the upper third
behave more like a colon or a rectal cancer? Dis Colon Rectum 2010; 53:761-70.
6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 21 2004; 351:1731-40.
7. Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus
selective postoperative chemoradiotherapy in patients with rectal cancer (MRC
CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 7 2009;
8. Lebwohl B, Ballas L, Cao Y, et al. Treatment interruption and discontinuation in
radiotherapy for rectal cancer. Cancer Invest 2010; 28:289-94.
9. Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course
preoperative radiotherapy combined with total mesorectal excision for rectal cancer:
increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer
group study. J Clin Oncol 2005; 23:6199-206.
10. Pietrzak L, Bujko K, Nowacki MP, et al. Quality of life, anorectal and sexual
functions after preoperative radiotherapy for rectal cancer: report of a randomised
trial. Radiother Oncol 2007; 84:217-25.

Sarah Popek et al
11. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in
adenocarcinoma of the rectum: final treatment results of a randomized trial and an
evaluation of late secondary effects. Dis Colon Rectum 1993; 36:564-72.
12. Minsky BD, Guillem JG. Multidisciplinary management of resectable rectal cancer.
New developments and controversies. Oncology (Williston Park) 2008; 22:1430-7.
13. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance
imaging in predicting curative resection of rectal cancer: prospective observational
study. BMJ 2006; 333:779.
14. Vliegen R, Dresen R, Beets G, et al. The accuracy of Multi-detector row CT for the
assessment of tumor invasion of the mesorectal fascia in primary rectal cancer.
Abdom Imaging 2008; 33:604-10.
15. Hildebrandt U, Feifel G. Preoperative staging of rectal cancer by intrarectal ultrasound. Dis Colon Rectum 1985; 28:42-6.
16. Kav T, Bayraktar Y. How useful is rectal endosonography in the staging of rectal
cancer? World J Gastroenterol 2010; 16:691-7.
17. Halefoglu AM, Yildirim S, Avlanmis O, et al. Endorectal ultrasonography versus
phased-array magnetic resonance imaging for preoperative staging of rectal cancer.
World J Gastroenterol 2008; 14:3504-10.
18. Puli SR, Reddy JB, Bechtold ML, et al. Accuracy of endoscopic ultrasound to
diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review.
Ann Surg Oncol 2009; 16:1255-65.
19. Edelman BR, Weiser MR. Endorectal ultrasound: its role in the diagnosis and
treatment of rectal cancer. Clin Colon Rectal Surg 2008; 21:167-77.
20. Harewood GC. Assessment of publication bias in the reporting of EUS performance
in staging rectal cancer. Am J Gastroenterol 2005; 100:808-16.
21. Shami VM, Parmar KS, Waxman I. Clinical impact of endoscopic ultrasound and
endoscopic ultrasound-guided fine-needle aspiration in the management of rectal
carcinoma. Dis Colon Rectum 2004; 47:59-65.
22. Bipat S, Glas AS, Slors FJ, et al. Rectal cancer: local staging and assessment of lymph
node involvement with endoluminal US, CT, and MR imaging--a meta-analysis.
Radiology 2004; 232:773-83.
23. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336:980-7.

24. Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting
benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005;
25. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined
with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;
26. Peeters KC, Marijnen CA, Nagtegaal ID, et al. The TME trial after a median
follow-up of 6 years: increased local control but no survival benefit in irradiated
patients with resectable rectal carcinoma. Ann Surg 2007; 246:693-701.
27. Julianov A. Chemoradiotherapy for rectal cancer. N Engl J Med 2005; 352:509-11;
author reply 509-11.
28. Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment
on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol
2004; 22:1785-96.
29. Simunovic M, Sexton R, Rempel E, et al. Optimal preoperative assessment and
surgery for rectal cancer may greatly limit the need for radiotherapy. Br J Surg 2003;
30. Willett CG, Badizadegan K, Ancukiewicz M, et al. Prognostic factors in stage T3N0
rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42:167-73.
31. Merchant NB, Guillem JG, Paty PB, et al. T3N0 rectal cancer: results following
sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999;
32. Nissan A, Stojadinovic A, Shia J, et al. Predictors of recurrence in patients with T2
and early T3, N0 adenocarcinoma of the rectum treated by surgery alone. J Clin
Oncol 2006; 24:4078-84.
33. Guillem JG, Diaz-Gonzalez JA, Minsky BD, et al. cT3N0 rectal cancer: potential
overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol
2008; 26:368-73.
34. Birgisson H, Pahlman L, Gunnarsson U, et al. Late gastrointestinal disorders after
rectal cancer surgery with and without preoperative radiation therapy. Br J Surg
2008; 95:206-13.

Clinical Colorectal Cancer Month 2011


Documents similaires

Fichier PDF 1 s2 0 s1533002811001071 main
Fichier PDF planas silva et al 2008
Fichier PDF carayol 2013 prevention tertiaire cancer
Fichier PDF does the surgical apgar score measure intraoperative
Fichier PDF surgical apgar outcome score perioperative risk assessment
Fichier PDF perte de poids preop et ewl

Sur le même sujet..